BRIEF: Hengrui executive to sell nearly 500,000 A-shares
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in…
BRIEF: Dobot partners with YSB on pharmacy-focused robots
Robot manufacturer Shenzhen Dobot Corp. Ltd. (2432.HK) on Tuesday announced a strategic collaboration with YSB Inc. (9885.HK) to jointly develop robots for pharmaceutical applications. The partnership will see Dobot spearhead…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
FAST NEWS: Simcere Pharma New Co-CEO Sends Investors Scurrying
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced late Wednesday that executive director Tang Renhong has been appointed as Co-CEO and will assist Chairman and CEO Ren Jinsheng in leading…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.
Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87%…
Recent Articles
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
1276.HK
600276.SHG
BRIEF: Dobot partners with YSB on pharmacy-focused robots
2432.HK
9885.HK
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK
2359.HK
RELATED ARTICLES
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG -
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
1276.HK 600276.SHG
-
BRIEF: China Ruyi raises $500 million in share placement at slight discount
0136.HK
-
BRIEF: Cloud Factory chairman to sell up to 15% stake
2512.HK
